Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-1 plus oxaliplatin versus S-1 alone as adjuvant therapy for stage II/IIIA gastric cancer
ChiCTR-TRC-11001560Phase 3Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Oct 2011
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of tegafur and oxaliplatin in gastric cancer (GC) (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: Recurrence-free survival. Started Oct 2011; status: recruiting.
02
Drugs
tegafuroxaliplatin
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on ChiCTR-TRC-11001560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-11001560.